No Data
QYUNS-B: 2024 ANNUAL REPORT
Chunxin Bio-B (02509) has signed an exclusive licensing agreement with Caldera Therapeutics for the development and commercialization of QX030N.
Zhuanxin Biotechnology-B (02509) announced that on April 23, 2025, the company will work with Caldera ...
Express News | Qyuns Therapeutics Co Ltd - Enters Exclusive License Agreement With Caldera Therapeutics
Qyuns Therapeutics Co., Ltd. (HKG:2509) Stock Rockets 32% But Many Are Still Ignoring The Company
Transsion Biotech-B (02509) released its annual performance, achieving an income of 0.159 billion yuan.
Sangfor Technologies-B (02509) announced the annual results for the year ending December 31, 2024, with the group's revenue in RMB...
Express News | Qyuns Therapeutics Co Ltd - FY Revenue RMB158.8 Mln